The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) was $308.00 for the day, up 0.88% from the previous closing price of $305.31. In other words, the price has increased by $0.88 from its previous closing price. On the day, 0.76 million shares were traded.
Ratios:
Our analysis of ALNY’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.98 and its Current Ratio is at 3.04. In the meantime, Its Debt-to-Equity ratio is 23.58 whereas as Long-Term Debt/Eq ratio is at 22.47.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Redburn Atlantic on March 31, 2025, initiated with a Buy rating and assigned the stock a target price of $353.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 30 ’25 when Greenstreet Yvonne sold 31,640 shares for $304.39 per share. The transaction valued at 9,630,902 led to the insider holds 48,948 shares of the business.
Greenstreet Yvonne sold 19,297 shares of ALNY for $5,904,882 on Jun 02 ’25. The Chief Executive Officer now owns 48,948 shares after completing the transaction at $306.00 per share. On Jun 02 ’25, another insider, Greenstreet Yvonne, who serves as the Officer of the company, bought 19,297 shares for $303.10 each.
Stock Price History:
Over the past 52 weeks, ALNY has reached a high of $308.93, while it has fallen to a 52-week low of $147.25. The 50-Day Moving Average of the stock is 16.23%, while the 200-Day Moving Average is calculated to be 17.34%.
Shares Statistics:
A total of 130.31M shares are outstanding, with a floating share count of 124.67M. Insiders hold about 4.38% of the company’s shares, while institutions hold 96.25% stake in the company.